GHRP-2

GHRP-2 is a ghrelin-mimetic growth hormone releasing peptide - it binds the same receptor as ghrelin and prompts the pituitary to release GH. Compared to ipamorelin, it produces somewhat stronger GH pulses and comes with a mild bump in appetite and a slight increase in cortisol and prolactin at higher doses. It occupies the middle ground between ipamorelin's clean selectivity and GHRP-6's pronounced hunger effects. Its primary goals are muscle building and recovery. Fat loss is a secondary benefit. It tends to be considered for patients where the appetite increase is not a drawback - or where a stronger GH pulse is prioritized. GHRP-2 is given as a subcutaneous injection of 100-300 mcg, one to three times daily, on an empty stomach. Timing on an empty stomach matters for the same reason as other GH secretagogues - elevated insulin blunts the GH response. Courses typically run three to six months. The main caution is a mild rise in cortisol and prolactin at higher doses. This is manageable and monitored, but it is worth noting for people sensitive to those hormones or running longer courses at higher doses. Like all GH-axis peptides, GHRP-2 is contraindicated in anyone with a cancer history and should not be combined with MK-677. It stacks well with CJC-1295 (no DAC). Its evidence base is classified as emerging - there is clinical and mechanistic data supporting its use, but it has not cleared the same regulatory bar as sermorelin or tesamorelin. Exact dosing and any stack decisions are made with your licensed provider in the PepDepo network at consult.